BioConsortia Raises $15M Series C+ Led by Otter Capital

BioConsortia Secures $15M Series C+

BioConsortia has raised a $15 million Series C+ round led by Otter Capital, the company's funding announcement confirmed. Otter Capital was the sole investor listed in the round.

What BioConsortia Does

BioConsortia is a microbial discovery and development company based in Davis, California. The company develops biological crop solutions spanning biofertilizers, biostimulants, and biocontrol products for row and specialty crops.

Its platform combines advanced microbial selection, gene editing, and rigorous field validation to deliver seed and soil treatments intended to perform consistently in commercial farming systems.

Lead Products and Commercial Partners

BioConsortia's lead products include:

• Zaffre — a biostimulant
• Always N — a nitrogen-fixing seed treatment

The company commercializes these products with partners including The Mosaic Company, H&T, and Nichino. Its commercial footprint spans the Americas, Europe, Asia, Australia, and New Zealand.

The Round at a Glance

• Company: BioConsortia
• Round type: Series C+
• Amount raised: $15,000,000 USD
• Lead investor: Otter Capital
• Investors: Otter Capital
• Announcement date: October 9, 2026

Why the Raise Matters

The Series C+ extends BioConsortia's funding at a stage where the company already has named commercial partners and products in market across multiple geographies. The round is led by a single investor, Otter Capital, which also stands as the only listed participant.

For a microbial discovery and development company, the combination of a discovery platform and established distribution relationships is the core of the investment case. BioConsortia's stated platform integrates microbial selection with gene editing and field validation — a pipeline-to-field approach aimed at consistency in commercial farming systems rather than laboratory-only results.

Product Portfolio Context

The company's portfolio addresses three categories of biological crop inputs:

• Biofertilizers, which support nutrient availability and uptake
• Biostimulants, including the lead product Zaffre
• Biocontrol products, which target crop protection needs

Always N, the company's nitrogen-fixing seed treatment, sits within the seed treatment category and is commercialized with partners.

What to Watch

With $15 million in new capital and an existing partner network that includes The Mosaic Company, H&T, and Nichino, BioConsortia is positioned to continue developing and commercializing its biological crop solutions. The company's ability to scale its lead products — Zaffre and Always N — across its existing geographic footprint is the central operational story to follow.

All figures, products, and partner details are as reported in the funding announcement dated October 9, 2026.